May 18, 2024 06:00 AM EDT

Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more

Amber Tong

Senior Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more

Amber Tong

Senior Editor

Sign up to read this article for free.

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

De-risking the patient journey in cell therapies: Six key considerations

Mega start­up watch; In­ter­view with Sid­dhartha Mukher­jee; Track­ing We­govy’s long-term ef­fects; Bio­gen’s ALS flop; and more

Amber Tong

Senior Editor

Sign up to read this article for free.

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

With new da­ta, As­traZeneca makes the case for its BTK in­hibitor in a first-line set­ting

Nurix’s pro­tein de­grad­er over­comes re­sis­tance to BTK mu­ta­tions in small leukemia study

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

De-risking the patient journey in cell therapies: Six key considerations